Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14285905 | 0.84 | ALDH1A1 (0.39) | ALDH1A1HTTBRD4CREBBPPOLB | |
| SCHEMBL14626447 | 0.83 | BRD4 (0.38) | ALDH1A1HTTBRD4CREBBPPOLB | |
| SCHEMBL5033157 | 0.79 | HTT (0.36) | ALDH1A1HTTPOLBMEN1KMT2A | |
| SCHEMBL5030919 | 0.71 | DAO (0.41) | ALDH1A1BRD4CREBBPPOLBDAO | |
| SCHEMBL5035229 | 0.69 | ALDH1A1 (0.38) | ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL5031758 | 0.69 | P2RX3 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14626453 | 0.67 | POLB (0.37) | ALDH1A1POLB | |
| SCHEMBL5030966 | 0.62 | POLB (0.38) | ALDH1A1HTTPOLBMEN1KMT2A | |
| SCHEMBL5030915 | 0.61 | GPR139 (0.30) | — | |
| SCHEMBL5035241 | 0.60 | MAPT (0.35) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910391-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | CYP4B1, CYP1B1, CYP11B1 | ALDH1A1 622/4885HTT 4695/4885BRD4 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.